VTGN logo

VistaGen Therapeutics (VTGN) Cash From Operations

Annual CFO

-$25.81 M
+$23.90 M+48.08%

March 31, 2024

Summary

Performance

1-Year Change

+48.08%

3-Year Change

-113.8%

5-Year Change

-77.68%

15-Year Change

-255.45%

VTGN Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.84%
VTGN annual cash flow from operations is higher than 41.84% of companies in Healthcare sector

High & Low

All-time High

-$6900.00

3-Year Low

-$49.72 M

Earnings dates

Last Annual Earnings Report Date

Mar 31, 2024
VTGN previous annual earnings announcement was published on Mar 31, 2024

Next Annual Earnings Report Date

Jun 11, 2025
VTGN next annual earnings announcement is scheduled for Jun 11, 2025

OtherVTGNcash flowmetrics:

Annual CFI

-$61.00 K
VTGN annual cash flow from investing activities is -$61.00 thousand

Annual CFF

$128.40 M
VTGN annual cash flow from financing activities is $128.40 million

Annual FCF

-$25.87 M
VTGN annual free cash flow is -$25.87 million

Annual CAPEX

$61.00 K
VTGN annual capital expenditures is $61.00 thousand

Quarterly CFO

-$10.28 M
+$606.00 K+5.57%

December 31, 2024

Summary

Performance

3-Month Change

+5.57%

1-Year Change

+5.42%

3-Year Change

+5.42%

5-Year Change

+5.42%

VTGN Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

31.32%
VTGN quarterly cash flow from operations is higher than 31.32% of companies in Healthcare sector

High & Low

All-time High

$1.00 M
VTGN quarterly cash flow from operations is currently -1124.21% below its historical high of $1.00 million

3-Year Low

-$16.34 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
VTGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Jun 11, 2025
VTGN next earnings announcement is scheduled for Jun 11, 2025

OtherVTGNcash flowmetrics:

Quarterly CFI

-$422.00 K
VTGN quarterly cash flow from investing activities is -$422.00 thousand

Quarterly CFF

$1.17 M
VTGN quarterly cash flow from financing activities is $1.17 million

Quarterly FCF

-$10.28 M
VTGN quarterly free cash flow is -$10.28 million

Quarterly CAPEX

$0.00
VTGN quarterly capital expenditures is $0.00

TTM CFO

-$39.02 M
-$5.53 M-16.52%

December 31, 2024

Summary

Performance

3-Month Change

-16.52%

1-Year Change

-35.53%

3-Year Change

-35.53%

5-Year Change

-35.53%

VTGN TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

32.63%
VTGN TTM cash flow from operations is higher than 32.63% of companies in Healthcare sector

High & Low

All-time High

-$300.00

3-Year Low

-$59.94 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
VTGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

Jun 11, 2025
VTGN next earnings announcement is scheduled for Jun 11, 2025

OtherVTGNcash flowmetrics:

TTM CFI

-$13.70 M
VTGN TTM cash flow from investing activities is -$13.70 million

TTM CFF

$879.00 K
VTGN TTM cash flow from financing activities is $879.00 thousand

TTM FCF

-$39.15 M
VTGN TTM free cash flow is -$39.15 million

TTM CAPEX

$132.00 K
VTGN TTM capital expenditures is $132.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

VTGN Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+48.1%+5.4%-35.5%
3 y3 years-113.8%+5.4%-35.5%
5 y5 years-77.7%+5.4%-35.5%

VTGN Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-113.8%+48.1%-116.6%+37.1%-51.2%+34.9%
5 y5-year-113.8%+48.1%-1124.2%+37.1%-350.5%+34.9%
alltimeall time<-9999.0%+48.1%-1124.2%+37.1%<-9999.0%+34.9%

VistaGen Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-
-$10.28 M(-5.6%)
-$39.02 M(+16.5%)
Sep 2024
-
-$10.89 M(+0.2%)
-$33.49 M(+16.3%)
Jun 2024
-
-$10.87 M(+55.6%)
-$28.79 M(+11.5%)
Mar 2024
-$25.81 M(-48.1%)
-$6.99 M(+47.1%)
-$25.81 M(-1.9%)
Dec 2023
-
-$4.75 M(-23.3%)
-$26.30 M(-16.5%)
Sep 2023
-
-$6.19 M(-21.6%)
-$31.49 M(-24.4%)
Jun 2023
-
-$7.89 M(+5.6%)
-$41.64 M(-16.2%)
Mar 2023
-$49.72 M(+9.9%)
-$7.47 M(-24.8%)
-$49.72 M(-14.0%)
Dec 2022
-
-$9.93 M(-39.2%)
-$57.83 M(-3.5%)
Sep 2022
-
-$16.34 M(+2.3%)
-$59.94 M(+8.9%)
Jun 2022
-
-$15.97 M(+2.4%)
-$55.05 M(+21.6%)
Mar 2022
-$45.26 M(+274.8%)
-$15.59 M(+29.4%)
-$45.26 M(+29.5%)
Dec 2021
-
-$12.05 M(+5.2%)
-$34.95 M(+25.3%)
Sep 2021
-
-$11.45 M(+85.5%)
-$27.89 M(+80.7%)
Jun 2021
-
-$6.17 M(+16.9%)
-$15.44 M(+27.9%)
Mar 2021
-$12.07 M(-23.4%)
-$5.28 M(+5.9%)
-$12.07 M(+28.8%)
Dec 2020
-
-$4.99 M(-597.0%)
-$9.37 M(+8.2%)
Sep 2020
-
$1.00 M(-135.8%)
-$8.66 M(-37.2%)
Jun 2020
-
-$2.81 M(+8.8%)
-$13.80 M(-12.4%)
Mar 2020
-$15.76 M(+8.5%)
-$2.58 M(-39.7%)
-$15.76 M(-5.8%)
Dec 2019
-
-$4.28 M(+3.5%)
-$16.73 M(+2.3%)
Sep 2019
-
-$4.14 M(-13.1%)
-$16.36 M(+1.3%)
Jun 2019
-
-$4.76 M(+33.9%)
-$16.15 M(+11.2%)
Mar 2019
-$14.53 M(+60.4%)
-$3.56 M(-9.0%)
-$14.53 M(+7.0%)
Dec 2018
-
-$3.91 M(-0.5%)
-$13.57 M(+12.1%)
Sep 2018
-
-$3.93 M(+25.3%)
-$12.11 M(+20.4%)
Jun 2018
-
-$3.14 M(+20.4%)
-$10.06 M(+11.1%)
Mar 2018
-$9.06 M(+24.7%)
-$2.60 M(+6.5%)
-$9.06 M(+16.9%)
Dec 2017
-
-$2.44 M(+30.3%)
-$7.75 M(+4.7%)
Sep 2017
-
-$1.88 M(-12.1%)
-$7.40 M(-4.2%)
Jun 2017
-
-$2.13 M(+64.9%)
-$7.73 M(+6.4%)
Mar 2017
-$7.26 M
-$1.29 M(-38.2%)
-$7.26 M(-0.2%)
Dec 2016
-
-$2.10 M(-4.9%)
-$7.28 M(+14.6%)
Sep 2016
-
-$2.20 M(+31.8%)
-$6.35 M(+12.3%)
DateAnnualQuarterlyTTM
Jun 2016
-
-$1.67 M(+27.6%)
-$5.66 M(+17.6%)
Mar 2016
-$4.81 M(+73.7%)
-$1.31 M(+12.0%)
-$4.81 M(+9.4%)
Dec 2015
-
-$1.17 M(-22.4%)
-$4.39 M(+23.2%)
Sep 2015
-
-$1.51 M(+82.9%)
-$3.56 M(+38.2%)
Jun 2015
-
-$823.30 K(-8.0%)
-$2.58 M(-6.8%)
Mar 2015
-$2.77 M(+30.2%)
-$894.50 K(+162.3%)
-$2.77 M(+18.3%)
Dec 2014
-
-$341.00 K(-34.6%)
-$2.34 M(-0.1%)
Sep 2014
-
-$521.60 K(-48.4%)
-$2.34 M(-2.6%)
Jun 2014
-
-$1.01 M(+116.6%)
-$2.41 M(+13.2%)
Mar 2014
-$2.13 M(-38.6%)
-$467.10 K(+36.4%)
-$2.13 M(-19.1%)
Dec 2013
-
-$342.50 K(-41.4%)
-$2.63 M(-19.1%)
Sep 2013
-
-$584.60 K(-20.1%)
-$3.25 M(-16.7%)
Jun 2013
-
-$731.80 K(-24.6%)
-$3.90 M(+12.6%)
Mar 2013
-$3.46 M(-2.9%)
-$970.00 K(+0.8%)
-$3.46 M(+7.8%)
Dec 2012
-
-$962.60 K(-22.0%)
-$3.21 M(-2.9%)
Sep 2012
-
-$1.23 M(+316.7%)
-$3.31 M(+19.2%)
Jun 2012
-
-$296.20 K(-58.8%)
-$2.78 M(-22.2%)
Mar 2012
-$3.57 M(>+9900.0%)
-$718.60 K(-32.1%)
-$3.57 M(+25.2%)
Dec 2011
-
-$1.06 M(+50.7%)
-$2.85 M(+58.9%)
Sep 2011
-
-$702.20 K(-35.4%)
-$1.79 M(+64.4%)
Jun 2011
-
-$1.09 M(>+9900.0%)
-$1.09 M(>+9900.0%)
Mar 2011
-
-$1700.00(-19.0%)
-$8600.00(+24.6%)
Dec 2010
-$6900.00(-69.7%)
-$2100.00(+2000.0%)
-$6900.00(-5.5%)
Sep 2010
-
-$100.00(-97.9%)
-$7300.00(+1.4%)
Jun 2010
-
-$4700.00(<-9900.0%)
-$7200.00(+50.0%)
Mar 2010
-
$0.00(-100.0%)
-$4800.00(-78.9%)
Dec 2009
-$22.80 K(+58.3%)
-$2500.00(<-9900.0%)
-$22.80 K(-33.5%)
Sep 2009
-
$0.00(-100.0%)
-$34.30 K(-0.3%)
Jun 2009
-
-$2300.00(-87.2%)
-$34.40 K(+6.8%)
Mar 2009
-
-$18.00 K(+28.6%)
-$32.20 K(+122.1%)
Dec 2008
-$14.40 K
-$14.00 K(>+9900.0%)
-$14.50 K(+2800.0%)
Sep 2008
-
-$100.00(0.0%)
-$500.00(+25.0%)
Jun 2008
-
-$100.00(-66.7%)
-$400.00(+33.3%)
Mar 2008
-
-$300.00(-86.4%)
-$300.00(-86.4%)
Mar 2007
-
-$2200.00
-$2200.00

FAQ

  • What is VistaGen Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics annual CFO year-on-year change?
  • What is VistaGen Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics quarterly CFO year-on-year change?
  • What is VistaGen Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for VistaGen Therapeutics?
  • What is VistaGen Therapeutics TTM CFO year-on-year change?

What is VistaGen Therapeutics annual cash flow from operations?

The current annual CFO of VTGN is -$25.81 M

What is the all time high annual CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high annual cash flow from operations is -$6900.00

What is VistaGen Therapeutics annual CFO year-on-year change?

Over the past year, VTGN annual cash flow from operations has changed by +$23.90 M (+48.08%)

What is VistaGen Therapeutics quarterly cash flow from operations?

The current quarterly CFO of VTGN is -$10.28 M

What is the all time high quarterly CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high quarterly cash flow from operations is $1.00 M

What is VistaGen Therapeutics quarterly CFO year-on-year change?

Over the past year, VTGN quarterly cash flow from operations has changed by +$589.00 K (+5.42%)

What is VistaGen Therapeutics TTM cash flow from operations?

The current TTM CFO of VTGN is -$39.02 M

What is the all time high TTM CFO for VistaGen Therapeutics?

VistaGen Therapeutics all-time high TTM cash flow from operations is -$300.00

What is VistaGen Therapeutics TTM CFO year-on-year change?

Over the past year, VTGN TTM cash flow from operations has changed by -$10.23 M (-35.53%)